<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Aamdal, Steinar</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">A Paradigm Shift in Early Drug Development: Individualizing to More Patient Benefit</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-7</style></pages><abstract><style  face="normal" font="default" size="100%">With the increasing the use of biomarkers in cancer treatment, the emphasis on selecting the right treatment for the right patient takes on added significance in early drug development. This article discusses the difficulties inherent in selecting patients for early drug-development studies.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>